Public Affairs Manager - COPAC Vacunas
About the job
- Progressive experience in public affairs, government relations, or policy development in vaccines, biotechnology, or healthcare.
- A proven record in government relations and advocacy related to vaccine or immunization policy in the region; experience in COPAC countries is highly valued.
- Experience engaging health authorities, ministries, social security institutions, and multilateral organizations in the context of vaccine access.
- Success designing and implementing public affairs strategies with measurable results in vaccine policy and market access.
- Ability to navigate complex regulatory and political environments across multiple countries simultaneously.
- Experience building and managing multi-stakeholder coalitions.
- A required undergraduate degree.
- Deep understanding of immunization plans, vaccine introduction mechanisms, stakeholder ecosystems, and regional immunization strategies.
- Ability to build relationships with government officials, health ministries, payers, patient organizations, and medical societies relevant to vaccine access.
- Demonstrated ability to design and execute advocacy campaigns that achieve measurable changes in vaccine policy.
- Ability to identify policy trends, translate them into actionable plans, and align public affairs strategy with business objectives.
- Business-fluent Spanish and English.
- Design and execute public affairs strategies focused on vaccines and develop a multi-year roadmap.
- Lead modernization of national immunization programs in COPAC countries and drive introduction of new vaccines, including FLU, IPV, hexavalent, and RSV vaccines.
- Build relationships with health authorities, social security institutions, PAHO/WHO, multilateral organizations, NITAGs, pediatric societies, civil society organizations, media, and immunization opinion leaders.
- Develop evidence-based advocacy campaigns with measurable vaccine-policy changes; navigate complex regulatory and political environments; lead health technology assessment processes for vaccines; and develop access frameworks and immunization legislation.
- Lead multi-stakeholder coalitions and public-private partnerships, and drive synergies across prevention and treatment portfolios to position Sanofi as a strategic partner in health innovation.
- Develop evidence-based advocacy projects with measurable changes and manage crises using rapid-response protocols and ethical standards.
- Experience in the public and private sectors is a relevant differentiator.
- Knowledge of pharmaceutical market access.
- A master's degree in Public Health, Health Policy, Epidemiology, or Political Science, or an MBA focused on health.
- Additional certifications in Immunization Policy, Market Access, or Government Affairs.
- Portuguese or other COPAC-region languages.
About the company
Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Get referred to Sanofi
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
- June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
- Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.
What critics are saying
- Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
- Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
- Dupixent concentration makes 2030s patent loss an existential revenue shock.
What makes Sanofi unique
- Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
- October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
- Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Health Insurance
- Professional Development Budget
- Parental Leave